Latest Quarterly Reports News

Legacy Iron Ore Limited reports robust progress in its December 2024 quarter, highlighted by significant gold intersections at Mount Celia and advancing feasibility studies at Mount Bevan magnetite project.

Xstate Resources reports steady oil and gas production while navigating ASX suspension and preparing for capital raising tied to a new project announcement.

Stavely Minerals' latest quarterly report reveals continued exploration progress at its key Victorian and Western Australian projects, alongside a successful capital raise to fund further drilling and geophysical surveys.

Zeus Resources Ltd has successfully reinstated its securities on the ASX and raised over $1.2 million through a Share Purchase Plan, Priority Options Offer, and Placement, advancing exploration in uranium, lithium, and rare earth projects across South Australia and Western Australia.

Carnavale Resources has reported significant drilling success at its Kookynie Gold Project, extending known high-grade gold lodes and discovering a new lode, Tiptoe, with promising mineralisation. The company is advancing exploration and development plans while divesting non-core assets to sharpen its focus on gold.

Hudson Investment Group signals potential corporate restructure as it explores sale and joint venture options for key Queensland and NSW properties.

Unico Silver has completed its acquisition of the Joaquin silver district and launched a fully funded 50,000m drill program, revealing exceptional high-grade mineralisation across multiple prospects in Santa Cruz, Argentina.

Brazilian Rare Earths Limited reports unprecedented ultra-high-grade rare earth intercepts and significant district-scale mineral discoveries at its Monte Alto project, alongside key permitting milestones advancing its mining ambitions.

Iltani Resources reports breakthrough drilling results at its Orient Silver-Indium Project, delivering Australia’s highest-grade silver-indium intercepts to date, alongside promising antimony mineralisation at Antimony Reward.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Develop Global Limited reported a robust increase in cash reserves for the December 2024 quarter, driven by significant financing inflows despite ongoing operational and investing outflows.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.